Lay media reporting of rosiglitazone risk: extent, messaging and quality of reporting
<p>Abstract</p> <p>Background</p> <p>A meta-analysis suggested the use of rosiglitazone was associated with an increased risk for cardiovascular (CV) events. Rosiglitazone remained available for use as more definitive safety trials were ongoing. This issue was reported...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-07-01
|
| Series: | Cardiovascular Diabetology |
| Online Access: | http://www.cardiab.com/content/8/1/40 |